secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001193125-24-245704
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M
--------------------------------------------------------------------------------

- Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.
- Mean annualized eGFR slope of -0.6 mL/min/1.73m2/year; 90% treatment completion rate.
- Phase 3 ORIGIN 3 topline expected Q2 2025; BLA submission planned H2 2025; commercial launch target 2026.
- Preliminary unaudited cash, cash equivalents and marketable securities ~$353.2M as of Sep 30, 2024.
- Data simultaneously published in Journal of the American Society of Nephrology; presented at ASN Kidney Week.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524245704/0001193125-24-245704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524245704/d891191d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-245704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer